Posted by Michael Wonder on 28 Feb 2020
Biohaven's Nurtec ODT (rimegapant) receives FDA approval for the acute treatment of migraine in adults
27 February 2020 - First and only calcitonin gene-related peptide receptor antagonist available in a fast-acting orally disintegrating tablet.
Biohaven Pharmaceutical today announced that the U.S. FDA has approved Nurtec ODT (rimegepant) for the acute treatment of migraine in adults.
Nurtec ODT is the first FDA approved product for Biohaven, a company dedicated to advancing innovative therapies for neurological diseases.
